Oxaliplatin Injection, Solution
Product Images NDC 43066-014

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 43066-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical-structure (Oxaliplatin Baxter 01)

Chemical structure of the active ingredient Oxaliplatin, showing a platinum (Pt) atom coordinated with a cyclohexane diamine group and two oxalate ligands.*

FDA Label Image

Figure-1 (Oxaliplatin Baxter 02)

A Kaplan-Meier curve graph showing Disease-Free Survival (DFS) probability over time in months for two treatment arms: FOLFOX4 (solid line) and LV5FU2 (dashed line). The graph includes the number of events and patients at risk at various time points, along with a hazard ratio (0.80) and statistical significance (p=0.003).*

FDA Label Image

Figure-2 (Oxaliplatin Baxter 03)

A line graph showing DFS (disease-free survival) probability over time in months, comparing two treatment arms: FOLFOX4 (solid line) and LV5FU2 (dashed line) in Stage III patients. The graph includes hazard ratio and p-value indicating a statistical comparison between treatments.*

FDA Label Image

Figure-3 (Oxaliplatin Baxter 04)

A survival curve chart showing the percentage of patients surviving over 24 months. It compares three treatment groups: Oxaliplatin plus 5-FU/LV, Oxaliplatin plus Irinotecan, and Irinotecan plus 5-FU/LV, with median survival times of 19.4, 17.6, and 14.6 months respectively. The x-axis represents time in months, and the y-axis shows the percentage of patients surviving.*

FDA Label Image

50mg-carton (Oxaliplatin Baxter 05)

Carton label for Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) sterile aqueous solution for intravenous use. It is a single-dose vial, preservative-free, and marked as a cytotoxic agent. The label includes usage instructions, storage guidelines, manufacturer Baxter Healthcare Corporation, and relevant cautions for handling and dosage.*

FDA Label Image

100mg-carton (Oxaliplatin Baxter 06)

Box packaging label for Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) intravenous solution by Baxter Healthcare Corporation. The label indicates a single-dose vial, sterile aqueous solution, preservative-free, and cytotoxic agent caution. It includes storage instructions, dilution warnings, and manufacturing details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.